VKH
PGNX

Virtu KCG Holdings’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Virtu KCG Holdings’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		$152K Sell
22,433
-56,936
-72% -$420K ﹤0.01% 2288
2017
Q1 		$749K Buy
79,369
+30,533
+63% +$305K 0.02% 966
2016
Q4 		$422K Buy
48,836
+12,991
+36% +$96K 0.01% 1697
2016
Q3 		$227K Sell
35,845
-7,867
-18% -$47.6K 0.01% 2249
2016
Q2 		$184K Buy
43,712
+18,142
+71% +$87.6K ﹤0.01% 2351
2016
Q1 		$111K Buy
25,570
+293
+1% +$1.3K ﹤0.01% 2307
2015
Q4 		$155K Sell
25,277
-8,750
-26% -$57.4K ﹤0.01% 2841
2015
Q3 		$195K Sell
34,027
-12,725
-27% -$97.6K ﹤0.01% 2584
2015
Q2 		$349K Buy
46,752
+32,270
+223% +$195K 0.01% 1880
2015
Q1 		$87K Sell
14,482
-11,810
-45% -$74.3K ﹤0.01% 2687
2014
Q4 		$199K Buy
26,292
+12,334
+88% +$73.8K ﹤0.01% 2893
2014
Q3 		$72K Buy
+13,958
New +$69.6K ﹤0.01% 3263
2014
Q2 		– Sell
-12,578
Closed -$51K – 4196
2014
Q1 		$51K Buy
+12,578
New +$64.3K ﹤0.01% 3332
2013
Q4 		– Sell
-20,267
Closed -$102K – 4402
2013
Q3 		$102K Buy
+20,267
New +$110K ﹤0.01% 3361

Other funds holding PGNX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
PFC
Phocas Financial Corp Alameda, California $637M AUM 39.08% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Virtu KCG Holdings's PGNX Position: Q2 2017 in Review

Virtu KCG Holdings reduced its Progenics Pharmaceuticals Inc (PGNX) stake by 72% in Q2 2017, selling an estimated $420K and leaving 22,433 shares worth $152K. The position accounts for ﹤0.01% of the portfolio, ranked #2288.

Virtu KCG Holdings first reported a position in PGNX in Q3 2013 and has held it in 14 quarters since. The position peaked at $749K in Q1 2017. 152 funds tracked by Wall St. Rank hold PGNX as of Q2 2017.

  • Virtu KCG Holdings held 22,433 shares of Progenics Pharmaceuticals Inc worth $152K as of Q2 2017.
  • Virtu KCG Holdings sold 56,936 Progenics Pharmaceuticals Inc shares in Q2 2017, an estimated $420K.
  • Progenics Pharmaceuticals Inc made up ﹤0.01% of Virtu KCG Holdings's portfolio in Q2 2017, its #2288 holding.
  • Virtu KCG Holdings first reported a position in Progenics Pharmaceuticals Inc in Q3 2013 and has held it in 14 quarters since.
  • Virtu KCG Holdings's Progenics Pharmaceuticals Inc position peaked at $749K in Q1 2017.
  • 152 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q2 2017.

Based on Virtu KCG Holdings's 13F filing for Q2 2017, filed 11 Aug 2017.